EMEA Gives Pfizer One Year To Provide Data For Bextra Reintroduction
This article was originally published in The Pink Sheet Daily
Executive Summary
European Medicines Agency concludes its review of the COX-2 class with formal recommendation to remove Bextra from the market and additional contraindications and warnings for class labeling. The agency will now turn its attention to the safety profile of “some conventional” NSAIDs.
You may also be interested in...
NSAID Safety Data Merit No Further Action, EMEA Committee Says
However, the Committee for Medicinal Products for Human Use recommends consistent labeling at the national level.
NSAID Safety Data Merit No Further Action, EMEA Committee Says
However, the Committee for Medicinal Products for Human Use recommends consistent labeling at the national level.
EMEA Recommends No New Action On Non-Selective NSAID Thrombotic Risk
European Medicines Agency is still reviewing gastrointestinal and serious skin infection safety.